The overall goals of my laboratory efforts are to develop and implement new ways to use the immune system to treat cancer.

Some of our ongoing projects include:

  • Investigation of the GITR pathway as it relates to regulatory and effector T cells.
  • Use of OX40 agonists alone and in combination with chemotherapy.
  • Exploration of the role of myeloid derived suppressor cells in tumor immunity.

We are also closely aligned with the Ludwig Center for Cancer Immunity and work closely with that group to monitor immune responses in patients receiving experimental immunotherapy treatments.


Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Jr., Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-26

Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-20.

Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, Benson B, Allison JP, Lesokhin AM, Gnjatic S, Wolchok JD. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012 Mar 8;366(10):925-31.

Hirschhorn-Cyerman D, Budhu S, Kitano S, Liu  C, Zhao F, Zhong H, Lesokhin A, Avogadri-Connors F, Yuan J, Li Y, Houghton AN, Merghoub T, Wolchok JD. Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. J Exp Med, 2012 Sept 24; 209(11) 2113-2126.

Wolchok JD, Kluger H, Callahan, MK, Postow, MA, Rizvi NA, Lesokhin, AM, Segal NH, Ariyan CE, Gordon RA, Reed, K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta, MA,  Sznol M.   Safety and clinical activity of combined PD-1 (nivolumab) and CTLA-4 (ipilimumab) blockade in advanced melanoma patients. New Engl J of Med., 2013 Jul 11;369(2):122-33.

Office phone:
646-888-2315 (Administrative Office); 646-888-2395 (Clinical Office)
Office fax:
Laboratory phone:
646-888-2585 (Laboratory Office)